Lead party: Acino International AG (lead investor/buyer)
Coverage: Meridian Capital (investment and transaction tracker; data from Partner Researchers, editorially reviewed).
Target: South African Prescription Medicines
Transaction type: Merger/Acquisition(M&A) · Asset class: Corporate Transactions · Strategy: Bolt-On · Instrument: Equity · Deal amount: US$123.2m · Equity stake: 1% · Implied EV: US$123.2m
Lead investor/buyer: Acino International AG · Investors/buyers: Acino International AG
Legal advisers: not identified in the source record.
Source: announced 22 October 2021. Original announcement: acino.swiss.


